NL2030303A - Labeling Method for Improving Signal Intensity of Time-Resolved Fluorescence and Application Thereof - Google Patents

Abstract

Labeling Method for Improving Signal Intensity of Time-Resolved Fluorescence and Application Thereof 5 The present invention discloses a labeling method for improving signal intensity of time-resolved fluorescence and an application thereof; and the labeling method can be applied in the detection of olaquindox or gentamicin. The olaquindox antibody complex immunolabelled by time-resolved fluorescence prepared in the present invention has a more stable structure, stronger fluorescence signal, and higher detection sensitivity. 10

Description

Labeling Method for Improving Signal Intensity of Time-Resolved Fluorescence and Application Thereof Technical Field The prevent invention belongs to the technical field of fluorescence immunoassay; and particularly relates to a labeling method for improving signal intensity of time-resolved fluorescence and an application thereof. Background Time-resolved fluorescence immunoassay (TRFIA} is a kind of booming high-sensitivity detection means in recent years. The principle of TRFIA is to use a chelating agent having a bifunctional group structure, one end thereof is bonded to lanthanide elements, and another end thereof is linked to a free amino group on an antibody {or antigen), thus preparing a lanthanide Eu®*-labeled antibody (or antigen) which is bonded to an antigen (or an antibody) in a sample to be tested to generate an antigen-antibody complex. At this time, the immune complex has a very weak fluorescence intensity; thereby it needs to add an enhancement solution, such that Eu? is dissociated from the complex, and may form a new complex with another chelating agent TTA under the synergistic effect of TOPO, Triton X-100 and the like in the enhancement solution; and the complex may emit very strong fluorescence to enhance million-fold fluorescent effect. Finally, the fluorescence intensity cps thereof is measured by a time resolution meter to determine the content of antigen in the sample.

The intensity of the fluorescence signal of rare earth element fluorescently-labeled antibody complex determines the detection sensitivity and stability of the method to a large extent, and is a key link to build the time-resolved fluorescence immunoassay. At present, the common bifunctional chelating agent used to label Eu?’ on an antibody mainly includes derivatives of ethylenediamie tetraacetic acid (EDTA) or diethylene triamine pentaacetic acid (DTPA) and other structural analogs having chelating functions.

For example, EDTA and Eu?’ ion form a metal-EDTA chelate more stable than the complex. In the prior art, EDTA and DTPA, these conventional chelating agents are open-loop and linear-chain structures; the complex of Eu** ion and chelating agent has a poor binding stability, which indicates that after being bonded, Eu® ion is easily dissociated from the complex, and the measured fluorescence signal weakens, and the detection sensitivity and stability will be influenced.

Therefore, it is very necessary and significant to provide a labeling method for improving signal intensity of time-resolved fluorescence and an application thereof.

Summary Directed to the above situation, and to overcome the shortcomings in the prior art, the present application provides a labeling method for improving signal intensity of time-resolved fluorescence and an application thereof.

To achieve the above objective, the prevent invention provides the following technical solution: A labeling method for improving signal intensity of time-resolved fluorescence, includes the following steps: (1) weighing and dissolving 4-7 mg 2-S-{4-aminobenzene)-1,4,7 triazacyclononane-1,4,7-triacetic acid (p-NH2-Bn-NOTA, abbreviated for NOTA) into a 1 mL 4-hydroxyethylpiperazine ethanesulfonic acid (HEPES) solution (0.01 mol-L%, pH=7.4) to be prepared into an NOTA chelating agent solution, where the solution is a solution A; {2} adding a 500-700 pL 20 mmol-L? glutaraldehyde solution to the solution A for reaction in dark place over the night at room temperature, where the solution is a solution B; (3) weighing and dissolving 20-30 mg purified monoclonal antibody lyophilized powder into a 3 ml HEPES solution {0.01 mol-L}, pH=7.4), and performing magnetic stirring for mixing evenly at room temperature, thus obtaining a solution C; (4) dropwisely adding the solution B to the solution C, then adjusting a pH value to 9.0, and stirring the mixed solution for reaction for 4-6 h in dark place at 4°C, thus obtaining a solution D; (5) loading the solution D to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES solution {0.01 mol-L'? pH=7.4), replacing the solution for once every 4 h, and 4-6 times in total, then, absorbing a reaction solution in the dialysis bag to obtain a solution E; (6) weighing 0.11-0.15 g EuCl3-6H,0, and preparing EuCl3:6H20 into a EuCls solution having a concentration of 3.3x102 mol-L? with 10 mL ultrapure water, thus obtaining a solution F; (7) taking and adding 200-400 ul solution F to the solution E for reaction for 4-6 hin dark place at room temperature, then placing the solution after reaction to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis, and replacing the solution for once every 4 h, and 4-5 times in total; centrifuging the dialyzed solution for 3-5 times with a 30 KDa ultrafiltration centrifugal tube at 7000-9000 rpm, and redissolving the remaining solution with a 5-10 ml HEPES solution (0.01 mol-L}, pH=7.4); where the prepared reaction solution is a monoclonal antibody complex immunolabelled by time-resolved fluorescence.

Further, the monoclonal antibody is an olaguindox monoclonal antibody or a gentamicin monoclonal antibody.

Provided is an application of 2-S-{(4-aminobenzene)-1,4,7 triazacyclononane-1,4,7-triacetic acid in improving signal intensity of time-resolved fluorescence.

The prevent invention has the following beneficial effects: The olaguindox or gentamicin antibody complex immunolabelled by time-resolved fluorescence prepared in the present invention has a more stable structure, such that the measured fluorescence signal is stronger and the detection sensitivity is higher.

The novel bifunctional chelating agent 2-S-(4-aminobenzene)-1,4,7 triazacyclononane-1,4,7-triacetic acid {p-NH2-Bn-NOTA, abbreviated for NOTA) has a feature of triaza closed-loop structure, thereby capable of binding to Eu?’ ion better; and the binding site is to wrap Eu?’ ions annularly, such that the complex is more stable, has better fluorescence intensity and signal, higher detection sensitivity, and better detection effect.

Brief Description of the Drawings FIG. 1 is a diagram showing a structure of NOTA, DTPA and EDTA.

FIG. 2 is a schematic diagram showing a route of preparing an olaguindox antibody-labeled complex.

FIG. 3 is a schematic diagram showing a route of preparing a gentamicin antibody-labeled complex.

Detailed Description of the Embodiments To describe the objective, technical solution and advantages of the present invention more clearly and apparently, the present application will be described and specified in combination with the drawings and examples.

The substances and detecting instrument used in the examples can be purchased by commercial approaches.

The PBS buffer solution used in the examples below, unless otherwise specified, is a 0.01 mol-L+ phosphate buffer solution (pH=7.4}; the CBS buffer solution used in the examples is a 0.05 molL? carbonate buffer solution (pH=9.6); bovine serum albumin is abbreviated for BSA; ovalbumin is abbreviated for OVA; keyhole limpet hemocyanin is abbreviated for KLH; olaquindox is abbreviated for OLA, and gentamicin is abbreviated for GM, 1M=1 mol-L.

Example 1 A labeling method for improving signal intensity of time-resolved fluorescence, included the following steps: Preparation of an olaguindox antibody-labeled complex (Eu**-NOTA-OLA-mAb) was set as an example for description: (1) 6 mg 2-S-{4-aminobenzene)-1,4,7 triazacyclononane-1,4,7-triacetic acid (p-NH2-Bn-NOTA, abbreviated for NOTA) were weighed and dissolved into a 2 mL HEPES solution (0.01 mol-L'}, pH=7.4) to be prepared into an NOTA chelating agent solution, where the solution was a solution A; {2} 520 pL 20 mmol-L? glutaraldehyde solution was added to the solution A for reaction in dark place over the night at room temperature, where the solution was a solution B; (3) 20 mg purified olaquindox monoclonal antibody lyophilized powder were weighed and dissolved into a 3 ml HEPES solution (0.01 mol-L?, pH=7.4), and magnetic stirring was performed for mixing evenly at room temperature, thus obtaining a solution C; in the example, the olaquindox monoclonal antibody {OLA-mAb) was prepared by a conventional method in the prior art (Reference: Yongyu Sang, and Renyao lin, Development on Anti-Olaguindox Monoclonal Antibodies and Establishment of ELISA

Method Thereof, Journal of Nuclear Agricultural Sciences, 2015, 29 (6):1081-1087). Ascitic fluid was purified by an octanoic acid-ammonium sulfate process, and then purified by passing a protein A affinity column, and lyophilized to obtain an OLA-mAb lyophilized powder.

5 (4) the solution B was dropwisely added to the solution C, then a pH value was adjusted to 9.0, and the mixed solution was stirred for reaction for 6 h in dark place at 4°C, thus obtaining a solution D; (5) the solution D was loaded to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES solution (0.01 mol-L! pH=7.4), the solution was replaced for once every 4 h, and 4-5 times in total, then, a reaction solution in the dialysis bag was absorbed to obtain a solution E; (6) 0.121 g EuCls-6H,0 was weighed and prepared into a EuCls solution having a concentration of 3.3x1072 mol-L? with 10 mL ultrapure water, thus obtaining a solution F; (7) 200 pl solution F was taken and added to the solution E for reaction for 4-6 h in dark place at room temperature, then the solution after reaction was placed to a dialysis bag having a molecular weight cut-off of 8 KDa, and the solution was replaced for once every 4 h during dialysis, and 4-5 times in total; the dialyzed solution was centrifuged for 3-5 times with a 30 KDa ultrafiltration centrifugal tube at 7000-9000 rpm, and the remaining solution was redissolved with a 5-10 mi HEPES solution {0.01 mol-L?, pH=7.4); where the prepared reaction solution was an olaquindox antibody complex immunolabelied by time-resolved fluorescence. Eu" content was measured by an Inductively Coupled Plasma-Atomic Emission Spectrometry (ICP-AES); a BCA protein concentration assay kit was used to measure the protein concentration in conjugates, then the protein concentration was converted into a molar concentration, and a binding ratio was calculated to 23:1, indicating a ratio of quantity; protein molecule: Eu*=1:23. The results indicated that the NOTA chelating agent was respectively bonded to olaquindox monoclonal antibody and Eu to successfully prepare an olaquindox antibody-labeled complex (Eu3*-NOTA-OLA-mAb). Verification of the preparation effect: It was measured by olaguindox TRFIA, and specific steps were as follows:

a. coating: a coating antigen (OLA-HS-OVA) was diluted by CBS {0.05 mol-L?, pH=9.6) to a concentration of 5 pg-mL?, and coated on a 96-well plate with 100 ul per well, and incubated for 2 h at 37°C in a constant temperature and humidity incubator, then the well plate was washed by a plate washing machine for 4 times, and pat-dried {the same below); b. blocking: 300 pL 2% (m/v) skimmed milk prepared by PBS {0.01 mol-Lt, pH=7.4) was added per well for incubation for 30 min at 37°C, then the well plate was washed for 4 times and pat-dried; c. adding olaquindox standard samples and Eu3*-NOTA-OLA-mAb labels: OLA standard substances having concentrations of the standard series were added to wells, 50 uL per well; then a europium-labeled antibody (Eu?-NOTA-OLA-mAb) was diluted to 2.5 ug:mL, and added to wells, 50 ul per well; after being oscillated for 30 s, the well plate was put to a 37°C incubator for incubation for 1 h, and the plate was washed for 4 timesand pat-dried; d. adding an enhancement solution: 200 uL enhancement solution was added per well for oscillatory reaction for 10 min in dark place at 37°C, and detected by a time-resolved fluorescence analyzer; e. reading and analysis: values {CPS) of the fluorometer were read to establish a standard curve and calculate ICso values and IC19 values.

Preparation of various reagents: A. Olaquindox standard solution having concentrations of the standard series: the concentrations were successively 0 ng:mL, 0.01 ng-mL?, 0.05 ng:mL, 0.1 ng-mL?, 0.5 ng'mb?, 1.0 ng-mt?, 2.0 ng-mL?, 4.0 ng-mL?, 8.0 ng-mL, 16.0 ng-mL?, and 32 ng-mL?, and obtained by diluting pure OLA; and the diluent was a 0.01 mol-L? phosphate buffer solution {pH=7.4) containing 5% (v/v) methanol.

B. Coating a buffer solution CBS: namely, a 0.05 mol-L? carbonate buffer solution (pH=9.6}; 1.49 g Na2CO3 and 2.93 g NaHCO: were weighed and adjusted to pH=9.6, and metered to a volume of 1000 mL with ultrapure water.

C. Blocking solution: namely, a 0.01 mol-L? phosphate buffer solution (PBS) (pH=7.4) containing 2% (m/v, g/mL) skimmed milk powder.

D. Cleaning solution: namely, a 0.01 mol-L! phosphate buffer solution (PBS) {pH=7.4) containing 0.05% (a volume fraction} Tween-20. E. Diluent: namely, a 0.01 mol-L! phosphate buffer solution (PBS) (pH=7.4) containing 5% (a volume fraction) methanol.

F. Enhancement solution: 120.0 mg a-thenoyltrifluoroacetone (TTA) and 386.6 mg trioctylphosphine oxide {TOPO) were accurately weighed and dissolved by adding 1.0 mL absolute ethyl alcohol, then 2.78 g potassium hydrogen phthalate and a small amount of deionized water were added, after dissolving at 40°C, 11.8 mL glacial acetic acid and 5 mL Triton X-100 were added, and finally metered to a volume of 2000 mL with water.

The pH value was adjusted to 3.0, suction filtration was performed with degreasing cotton, and filtrate was standing over the night, and kept in dark place via a 4°C refrigerator for further use.

G: Preparation of OLA-HS-OVA: a conventional method in the prior art was used for preparation available, and specifically as follows,

2.106 g olaquindox and 1.60 g succinic anhydride were accurately added to a three-necked round-bottom flask, and 80 mL pyridine was added for reflux reaction for 4 h at 115°C, the pyridine was removed by evaporation under reduced pressure, 60 mL icy distilled water was added to the remaining mixture, and a pH value was adjusted to

2.0-3.0 by 2 mol-L? HCl, then the remaining solution stayed over the night at 4°C.

Afterwards, the remaining solution was subjected to suction filtration under reduced pressure, and washed by icy distilled water for 3 times, and dried by suction, and the obtained substance was OLA-HS;

14.5 mg OLA-HS were weighed and dissolved into 0.8 mi DMF, and 4.6 mg NHS and 8.2 mg DCC were added for stirring reaction for 10 h in dark place at room temperature. The reaction solution was centrifuged (2000 rpm, 10 min), precipitate was discarded and supernate was a reaction solution a.

20 mg OVA were weighed and dissolved into a 5 ml phosphate buffer solution (PBS, 0.01 mol-L, PH=7.4) to obtain a reaction solution b. The reaction solution b was put on a magnetic stirrer; 0.6 mi reaction solution a was slowly added to the reaction solution b dropwisely at 4°C, and stirred for reaction over the night at 4°C. In the following day, the reaction solution was put to a dialysis bag for dialysis for 4-5 times per day with a phosphate buffer solution {0.01 mol-L "+, pH=7.4), then dialyzed for 12 h by ultrapure water, and centrifuged; precipitate was discarded and supernate was subpackaged to obtain OLA-HS-OVA, and OLA-HS-OVA was kept at -20°C for further use.

Example 2 A labeling method for improving signal intensity of time-resolved fluorescence, included the following steps: Preparation of a gentamicin antibody-labeled complex (Eu*-NOTA-GM-mAb) was set as an example for description: (1) 5.5 mg 2-S-{4-aminobenzene)-1,4,7 triazacyclononane-1,4,7-triacetic acid {p-NH2-Bn-NOTA, abbreviated for NOTA) were weighed and dissolved into a 2 mL HEPES solution (0.01 mol-L?, pH=7.4) to be prepared into an NOTA chelating agent solution, where the solution was a solution A; {2} 520 pL 20 mmol-L* glutaraldehyde solution was added to the solution A for reaction in dark place over the night at room temperature, where the solution was a solution B; (3) 20 mg purified GM-mAb lyophilized powder were weighed and dissolved into a 3 mi HEPES solution (0.01 mol-L}, pH=7.4), and magnetic stirring was performed for mixing evenly at room temperature, thus obtaining a solution C; GM-mAb was prepared by a conventional method in the prior art (Reference: Renyao Jin, and Jianxiang Wu; Development on Gentamicin Monoclonal Antibodies and Establishment of ELISA Method Thereof, Journal of Nuclear Agricultural Sciences, 2013, 27 (1):88-92). After ascitic fluid was prepared, and roughly purified by octanoic acid-ammonium sulfate, and then purified by a Protein A affinity column, and lyophilized to obtain a GM-mAb lyophilized powder.

(4) the solution B was dropwisely added to the solution C, then a pH value was adjusted by NaOH to 9.0, and the mixed solution was stirred for reaction for 4-6 h in dark place at 4°C, thus obtaining a solution D; (5) the solution D was loaded to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES solution (0.01 mol-Lt pH=7.4), the solution was replaced for once every 4 h, and 4-5 times in total, then, a reaction solution was absorbed in the dialysis bag to obtain a solution E; (6) 0.121 g EuCl3-6H,0 was weighed and prepared into a EuCl3 solution having a concentration of 3.3x102 mol-L? with 10 mL ultrapure water, thus obtaining a solution F; (7) 250 pl solution F was taken and added to the solution E for reaction for 4-6 h in dark place at room temperature, then the solution after reaction was placed to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES (0.01 mol-Lt, pH=7.4) solution; and the solution was replaced for once every 4 h during dialysis, and 4-5 times in total; the dialyzed solution was centrifuged for 3-5 times with a 30 KDa ultrafiltration centrifugal tube at 7000-9000 rpm, and the remaining solution was redissolved with a 5-10 ml HEPES solution {0.01 mol-L?, pH=7.4); where the prepared reaction solution was a gentamicin antibody-labeled complex.

Eu% content was measured by an Inductively Coupled Plasma-Atomic Emission Spectrometry (ICP-AES); a BCA protein concentration assay kit was used to measure the protein concentration in conjugates, then the protein concentration was converted into a molar concentration, and a binding ratio was calculated to 19:1, indicating a ratio of quantity; protein molecule: Eu?*=1:19. The results indicated that the NOTA chelating agent was respectively bonded to gentamicin monoclonal antibody and Eu®* to successfully prepare a gentamicin antibody-labeled complex (Eu**-NOTA-GM-mAb). Effect detection It was measured by gentamicin TRFIA, and specific steps were as follows: a. coating: a coating antigen (GM-OVA) was diluted by CBS (0.05 mol-L}, pH=9.6) to a concentration of 5 pg-mL?, and coated on a 96-well plate with 100 uL per well, and incubated for 2 h at 37°C in a constant temperature incubator, then the well plate was washed by a plate washing machine for 4 times, and pat-dried (the same below); b. blocking: 300 pL 2% (m/v) skimmed milk prepared by PBS (0.01 mol-L%, pH=7.4) was added per well for incubation for 30 min at 37°C, then the well plate was washed for 4 times and pat-dried; c. adding gentamicin standard samples and Eu**-NOTA-GM-mAb labels: gentamicin standard substances having concentrations of the standard series were added to wells, 50 uL per well; then an europium-labeled antibody (Eu*-NOTA-GM-mAb) was diluted to

2.5 pg-mL?, and added to wells, 50 ub per well; after being oscillated for 30 s, the well plate was put to a 37°C incubator for incubation for 1 h, and the plate was washed for 4 times and pat-dried; d. adding an enhancement solution: 200 uL enhancement solution was added per well for oscillatory reaction for 10 min in dark place at 37°C. e. reading and analysis: values {CPS) of the fluorometer were read to establish a standard curve and calculate ICso values and IC19 values. Preparation of various reagents: A. Gentamicin standard solution having concentrations of the standard series: the concentrations were successively 0 ng-mL?, 1 ng-mL?, 2 ng-mL?, 4ng-mL?, 0.5 ng mL 8 ng:mt?, 16 ng:mL%, 32 ng:mL, 64 ng-mL?, and 128 ng:mLt, and obtained by diluting pure gentamicin; and the diluent is a 0.01 mol-L-1 phosphate buffer solution (pH=7.4). B. Coating buffer solution: namely, a 0.05 mol-Lt carbonate buffer solution (pH=9.6);

1.49 g Na2CO:3 and 2.93 g NaHCO; were weighed and adjusted to pH=9.6, and metered to a volume of 1000 mL with ultrapure water. C. Blocking solution: namely, a 0.01 mol-L! phosphate buffer solution (PBS) (pH=7.4) containing 2% (m/v, g+} skimmed milk powder. D. Cleaning solution: namely, a 0.01 mol-L? phosphate buffer solution (PBS) (pH=7.4) containing Tween-20 {volume fraction was 0.05%). E. Diluent: namely, a 0.01 mol-L! phosphate buffer solution (PBS) (pH=7.4). F. Enhancement solution: 120.0 mg a-thenoyltrifluoroacetone (TTA) and 386.6 mg trioctylphosphine oxide (TOPO) were weighed and dissolved by adding 1.0 mL absolute ethyl alcohol, then 2.78 g potassium hydrogen phthalate and a small amount of deionized water were added, after dissolving at 40°C, 11.8 mL glacial acetic acid and 5 mL Triton X-100 were added, and finally metered to a volume of 2000 mL with water. The pH value was adjusted to 3.0, suction filtration was performed with degreasing cotton, and filtrate was standing over the night, and kept in dark place via a 4°C refrigerator for further use. G: Synthesis of GM-OVA: a conventional method in the prior art was used for preparation available, and specifically as follows,

20 mg GM and 12 mg OVA were taken, and respectively dissolved by 1 ml ultrapure water; then GM solution was dropwisely added to OVA solution while stirring slowly; 62 mg carbodiimide {EDC) were weighed and dissolved into 1 ml ultrapure water, then the above mixed solution was added dropwisely, and stirred for reaction for 4h at room temperature; afterwards, the reaction product was loaded to a dialysis bag for dialysis for 2 d, and the solution was replaced for once every 4 h, after replacing for 4-5 times, the remaining solution was subpackaged, and kept at -20°C.

Comparative Example 1 Preparation of an olaguindox fluorescent antibody complex (Eu**-EDTA-OLA-mAb): (1) 5.5 mg EDTA was weighed and dissolved into a 1 mL 4-hydroxyethylpiperazine ethanesulfonic acid {HEPES) solution {0.01 mol-L?, pH=7.4) to be prepared into an EDTA chelating agent solution, where the solution was a solution A; {2} 520 uL 20 mmol-L? glutaraldehyde solution was added to the solution A for reaction in dark place over the night at room temperature, where the solution was a solution B; (3) 20 mg purified OLA-mAb lyophilized powder were weighed and dissolved into a 3 ml HEPES solution {0.01 mol-L?, pH=7.4), and magnetic stirring was performed for mixing evenly at room temperature, thus obtaining a solution C; and the preparation method of the OLA-mAb lyophilized powder was the same as that in Example 1; (4) the solution B was dropwisely added to the solution C, then a pH value was adjusted by NaOH to 9.0, and the mixed solution was stirred for reaction for 4-6 h in dark place at 4°C, thus obtaining a solution D; (5) the solution D was loaded to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES solution {0.01 mol-L'! pH=7.4), the solution was replaced for once every 4 h, and 4-5 times in total, then, a reaction solution was absorbed in the dialysis bag to obtain a solution E; (6) 0.121 g EuCl3-6H,0 was weighed and prepared into a EuCls solution having a concentration of 3.3x102 mol-L? with 10 mL ultrapure water, thus obtaining a solution F; (7) 200 uL solution F was taken and added to the solution E for reaction for 4-6 h in dark place at room temperature, then the solution after reaction was placed to a dialysis bag having a molecular weight cut-off of 8000 Da for dialysis by an HEPES (0.01 mol-L?,

pH=7.4) solution; and the solution was replaced for once every 4 h during dialysis, and 4-5 times in total; the dialyzed solution was centrifuged for 3-5 times with a 30 KDa ultrafiltration centrifugal tube at 7000-9000 rpm, and the remaining solution was redissolved with a 5-10 ml HEPES solution (0.01 mol-L%, pH=7.4); where the prepared reaction solution was an olaquindox antibody complex immunolabelled by time-resolved fluorescence.

Eu®* content was measured by an Inductively Coupled Plasma-Atomic Emission Spectrometry (ICP-AES); a BCA protein concentration assay kit was used to measure the protein concentration in conjugates, then the protein concentration was converted into a molar concentration, and a binding ratio was calculated to 10:1, indicating a ratio of quantity; protein molecule: Eu?’=1:10. The results indicated that EDTA was respectively bonded to olaquindox monoclonal antibody and Eu® to successfully prepare an olaguindox antibody-labeled complex.

Verification of the preparation effect: it was measured by olaguindox TRFIA, and specific steps were as follows: a. coating: a coating antigen (OLA-HS-OVA) was diluted by CBS {0.05 mol-L, pH=9.6) to a concentration of 5 pg-mL?, and coated on a 96-well plate with 100 uL per well, and incubated for 2 h at 37°C in a constant temperature and humidity incubator, then the well plate was washed by a plate washing machine for 4 times, and pat-dried {the same below); b. blocking: 300 uL 2% skimmed milk prepared by PBS (0.01 mol-L}, pH=7.4) was added per well for incubation for 30 min at 37°C, then the well plate was washed; c. olaquindox standard samples and Eu®*-EDTA-OLA-mAb labels: OLA standard substances having concentrations of the standard series were added to wells, 50 uL per well; then an europium-labeled antibody (Eu3*-EDTA-OLA-mAb) was diluted to 2.5 ug-mLt, and added to wells, 50 pL per well; after being oscillated for 30 5, the well plate was put to a 37°C incubator for incubation for 1 h, and the plate was washed; d. adding an enhancement solution: 200 uL enhancement solution was added per well for oscillatory reaction for 10 min in dark place at 37°C; e. reading and analysis: values {CPS) of the fluorometer were read to establish a standard curve and calculate ICsg values and IC10 values.

Comparative Example 2 Preparation of an olaquindox antibody-labeled complex (Eu?*-DTPA-OLA-mAb): (1) 5.5 mg p- NH»-Bn-DTPA {hereinafter referred to as DTPA) were weighed and dissolved into a 2 ml HEPES buffer solution {0.01 mol-Lt, pH=7.4) to be prepared into a DTPA chelating agent solution, where the reaction solution was a solution A; {2} 520 pL 20 mmol-L? glutaraldehyde solution was added to the solution A for reaction in dark place over the night at room temperature, where the solution was a solution B; (3) 20 mg purified OLA-mAb lyophilized powder were weighed and dissolved into a 3 ml HEPES solution {0.01 mol-L}, pH=7.4), and magnetic stirring was performed for mixing evenly at room temperature, thus obtaining a solution C; and the preparation method of the OLA-mAb lyophilized powder was the same as that in Example 1. The solution B was dropwisely added to the solution C, then a pH value was adjusted by NaOH to 9.0, and the mixed solution was stirred for reaction for 4-6 h in dark place at 4°C, thus obtaining a solution D; {4} the solution D was loaded to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES solution (0.01 mol-L! pH=7.4), the solution was replaced for once every 4 h, and 4-5 times in total, then, a reaction solution was absorbed in the dialysis bag to obtain a solution E; (5) 0.121 g EuCl3:6H20 was weighed and prepared into a EuCl3 solution having a concentration of 3.3x10°2 mol-L™! with 10 mL ultrapure water, thus obtaining a solution F; (6) 200 pL solution F was taken and added to the solution E for reaction for 4-6 h in dark place at room temperature, then the solution after reaction was placed to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES (0.01 mol-L, pH=7.4) solution; and the solution was replaced for once every 4 h during dialysis, and 4-5 times in total; the dialyzed solution was centrifuged for 3-5 times with a 30 KDa ultrafiltration centrifugal tube at 7000-9000 rpm, and the remaining solution was redissolved with a 5-10 ml HEPES solution (0.01 mol-L, pH=7.4); where the prepared reaction solution was an olaquindox antibody complex immunolabelled by time-resolved fluorescence.

Eu? content was measured by an inductively Coupled Plasma-Atomic Emission

Spectrometry (ICP-AES); a BCA protein concentration assay kit was used to measure the protein concentration in conjugates, then the protein concentration was converted into a molar concentration, and a binding ratio was calculated to 8:1, indicating a ratio of quantity; protein molecule: Eu®*= 1:8. The results indicated that DTPA was respectively bonded to olaquindox monoclonal antibody and Eu?" to successfully prepare an olaguindox antibody-labeled complex (Eu?- DTPA -OLA-mAb). Effect detection: It was measured by Olaquindox TRFIA, and specific steps were as follows: a. coating: a coating antigen (OLA-HS-OVA) was diluted by CBS (0.05mol-Lt, pH=9.6} to a concentration of 5 ug-mL?, and coated on a 96-well plate with 100 pL per well, and incubated for 2 h at 37°C in a constant temperature incubator, then the well plate was washed by a plate washing machine for 4 times, and pat-dried (the same below); b. blocking: 300 uL 2% (m/v) skimmed milk prepared by PBS {0.01 mol-Lt, pH=7.4) was added per well for incubation for 30 min at 37°C, then the well plate was washed for 4 times and pat-dried; c. adding olaquindox standard samples and Eu?'-DTPA-OLA-mAb labels: OLA standard solution having concentrations of the standard series was added to wells, 50 ul per well; then an europium-labeled antibody (Eu?*-DTPA-OLA-mAb} was diluted to 2.5 ug-mL%, and added to wells, 50 ub per well; after being oscillated for 30 s, the well plate was put to a 37°C incubator for incubation for 1 h, and the plate was washed for 4 times and pat-dried; d. adding an enhancement solution: 200 uL enhancement solution was added per well for oscillatory reaction for 10 min in dark place at 37°C, and detected by a time-resolved fluorescence analyzer; e. reading and analysis: values {CPS) of the fluorometer were read to establish a standard curve and calculate ICso values and IC10 values.

Comparative Example 3 Preparation of a gentamicin antibody-labeled complex (Eu**-EDTA-GM-mADb): (1) 5.5 mg Aminobenzy-EDTA (hereinafter referred to as EDTA) were weighed and dissolved into a 2 ml HEPES buffer solution (0.01 mol-L, pH=7.4) to be prepared into an

EDTA chelating agent solution, where the reaction solution was a solution A; {2} 520 uL 20 mmol-L? glutaraldehyde solution was added to the solution A for reaction in dark place over the night at room temperature, where the solution was a solution B; (3) 20 mg purified GM-mAb lyophilized powder were weighed and dissolved into a 3 ml HEPES solution {0.01 mol-L}, pH=7.4), and magnetic stirring was performed for mixing evenly at room temperature, thus obtaining a solution C; and the preparation method of the GM-mAb lyophilized powder was the same as that in Example 2.

(4) the solution B was dropwisely added to the solution C, then a pH value was adjusted by NaOH to 9.0, and the mixed solution was stirred for reaction for 4-6 h in dark place at 4°C, thus obtaining a solution D; (5) the solution D was loaded to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES solution {0.01 mol-L'! pH=7.4), the solution was replaced for once every 4 h, and 5-6 times in total, then, a reaction solution was absorbed in the dialysis bag to obtain a solution E; (6) 0.121 g EuCl3-6H,0 was weighed and prepared into a EuClssolution having a concentration of 3.3x102 mol-L? with 10 mL ultrapure water, thus obtaining a solution F; (7) 250 pL solution F was taken and added to the solution E for reaction for 4-6 h in dark place at room temperature, then the solution after reaction was placed to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES (0.01 mol-L, pH=7.4) solution; and the solution was replaced during dialysis for once every 4 h, and 4-5 times in total; the dialyzed solution was centrifuged for 3-5 times with a 30 KDa ultrafiltration centrifugal tube at 7000-9000 rpm, and the remaining solution was redissolved with a 5-10 ml HEPES solution (0.01 mol-L, pH=7.4); where the prepared reaction solution was a gentamicin antibody-labeled complex.

Eu? content was measured by an inductively Coupled Plasma-Atomic Emission Spectrometry (ICP-AES); a BCA protein concentration assay kit was used to measure the protein concentration in conjugates, then the protein concentration was converted into a molar concentration, and a binding ratio was calculated to 7:1, indicating a ratio of quantity; protein molecule: Eu?’= 1:7. The results indicated that EDTA was respectively bonded to gentamicin monoclonal antibody and Eu? to successfully prepare a gentamicin antibody-labeled complex (Eu?*-EDTA-GM-mAb).

Effect detection It was measured by gentamicin TRFIA, and specific steps were as follows: a. coating: a coating antigen (GM-OVA) was diluted by CBS (0.05 mol-Lt, pH=9.6) to a concentration of 5 ug-mL?, and coated on a 96-well plate with 100 pL per well, and incubated for 2 h at 37°C in a constant temperature incubator, then the well plate was washed by a plate washing machine for 4 times, and pat-dried (the same below).

b. blocking: 300 nL 2% (m/v) skimmed milk prepared by PBS (0.01 mot-L%, pH=7.4) was added per well for incubation for 30 min at 37°C, then the well plate was washed for 4 times and pat-dried; c. adding gentamicin standard samples and Eu®-EDTA-GM-mAb labels: gentamicin standard substances having a concentration of the standard series were added to wells, 50 uL per well; then an europium-labeled antibody (Eu?*-EDTA-GM-mAb} was diluted to 2 ug:mLt, and added to wells, 50 pL per well; after being oscillated for 30 s, the well plate was put to a 37°C incubator for incubation for 1 h, and the plate was washed for 4 times and pat-dried; d. adding an enhancement solution: 200 uL enhancement solution was added per well for oscillatory reaction for 10 min in dark place at 37°C.

e. reading and analysis: values (CPS) of the fluorometer were read to establish a standard curve and calculate ICsp values and IC10 values.

Comparative Example 4 Preparation of a gentamicin antibody-labeled complex (Eu3*-DTPA-GM-mAb): (1) 5.5 mg p-NH2-Bn-DTPA were weighed and dissolved into a 2 ml HEPES buffer solution {0.01 mol-Lt, pH=7.4) to be prepared into a DTPA chelating agent solution, where the reaction solution was a solution A; (2) 520 pL 20 mmol-L? glutaraldehyde solution was added to the solution A for reaction in dark place over the night at room temperature, where the solution was a solution B;; (3) 20 mg purified GM-mAb lyophilized powder were weighed and dissolved into a 3 ml HEPES solution {0.01 mol-L, pH=7.4}, and magnetic stirring was performed for mixing evenly at room temperature, thus obtaining a solution C; and the preparation method of the GM-mAb lyophilized powder was the same as that in Example 2. (4) the solution B was dropwisely added to the solution C, then a pH value was adjusted by NaOH to 9.0, and the mixed solution was stirred for reaction for 4-6 h in dark place at 4°C, thus obtaining a solution D;

(5) the solution D was loaded to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES solution (0.01 mol-L! pH=7.4), the solution was replaced for once every 4 h, and 5 times in total, then, a reaction solution in the dialysis bag was absorbed to obtain a solution E;

(6) 0.121 g EuCl3:6H20 was weighed and prepared into a EuCl3 solution having a concentration of 3.3x10°2 mol-L™! with 10 mL ultrapure water, thus obtaining a solution F; {7} 250 uL solution F was taken and added to the solution E for reaction for 4-6 h in dark place at room temperature, then the solution after reaction was placed to a dialysis bag having a molecular weight cut-off of 8 KDa for dialysis by an HEPES (0.01 mol-L, pH=7.4) solution; and the solution was replaced for once every 4 h during dialysis, and 4-5 times in total; the dialyzed solution was centrifuged for 3-5 times with a 30 KDa ultrafiltration centrifugal tube at 7000-9000 rpm, and the remaining solution was redissolved with a 5-10 ml HEPES solution (0.01 mol-L%, pH=7.4); where the prepared reaction solution was a gentamicin antibody-labeled complex.

Eu?* content was measured by an Inductively Coupled Plasma-Atomic Emission Spectrometry (ICP-AES); a BCA protein concentration assay kit was used to measure the protein concentration in conjugates, then the protein concentration was converted into a molar concentration, and a binding ratio was calculated to 9:1, indicating a ratio of quantity; protein molecule: Eu*= 1:9. The results indicated that DTPA was respectively bonded to gentamicin monoclonal antibody and Eu? to successfully prepare a gentamicin antibody-labeled complex (Eu?- DTPA - GM-mAb). Effect detection It was measured by gentamicin TRFIA, and specific steps were as follows: a. coating: a coating antigen (GM-OVA) was diluted by CBS (0.05 mol-L?, pH=9.6) to a concentration of 4 pg-mL?, and coated on a 96-well plate with 100 ul per well, and incubated for 2 h at 37°C in a constant temperature incubator, then the well plate was washed by a plate washing machine for 4 times, and pat-dried (the same below); b. blocking: 300 uL 2% (m/v) skimmed milk prepared by PBS {0.01 mol-Lt, pH=7.4) was added per well for incubation for 30 min at 37°C, then the well plate was washed for 4 times and pat-dried;

c. adding gentamicin standard samples and Eu®-DTPA-GM-mAb labels: gentamicin standard solution (namely, GM standard substances) having a concentration of the standard series were successively added to wells, 50 pl per well; then an europium-labeled antibody (Eu**-DTPA-GM-mAb) was diluted to 2 ug-mL?, and added to wells, 50 uL per well; after being oscillated for 30 s, the well plate was put to a 37°C incubator for incubation for 1 h, and the plate was washed for 4 times and pat-dried; d. adding an enhancement solution: 200 uL enhancement solution was added per well for oscillatory reaction for 10 min in dark place at 37°C; e. reading and analysis: values {CPS) of the fluorometer were read to establish a standard curve and calculate ICso values and IC10 values.

Measured results of the olaquindox and gentamicin TRFIA were specifically shown in the table below: Table 1 Measured results of time-resolved fluorescence immunoassay on different antibody labeled complexes TRFIA detection Bi CPS value sensitivity ndi Labeled (ng/ml) ng complex Blank 50% rat control inhibition {Cio {Cso io value ratio Eu3*-NOTA-OLA 23: 333021 -mAb Example 16652471 0.18 3.54 1 79 1 Eu EDTA-OLA- 10: 161266 8062876 0.86 18.82 mAb Example 1 1 72

Bi TRFIA detection Labeled ndi CPS value sensitivity complex ng (ng/ml) Eu3*-DTPA-OLA- 147209 8:1 7358998 1.13 22.96 mAb Example 2 51 Eu**-NOTA-GM- 19: 300833 15039198 0,32 6.98 mAb Example 2 1 74 Eu*-EDTA-GM- 138468 7:1 6724019 2.48 37.61 mAb Example 3 26 Eu**-EDTA-GM- 151900 9:1 7401391 1.08 21.52 mAb Example 4 72 It can be seen from Table 1 that compared with Comparative Examples 1-2, the olaguindox fluorescently-labeled antibody complex prepared in Example 1 of the present invention has a higher binding force, lower IC10 and ICso detected by TRFIA; moreover, the fluorescently-labeled antibody complex prepared by using NOTA as a bifunctional chelating agent has a higher signal value CPS than that of the fluorescently-labeled antibody complex prepared by conventional DTPA and EDTA chelating agent derivatives. Similarly, compared with Comparative Examples 3-4, the gentamicin fluorescently-labeled antibody complex prepared in Example 2 has a higher binding force, lower Cio and ICsodetected by TRFIA; moreover, the prepared fluorescently-labeled antibody complex has a higher signal value CPS than that of the fluorescently-labeled antibody complex prepared by conventional DTPA and EDTA chelating agent derivatives. Therefore, the results in Table 1 may indicate that the complex prepared by NOTA is stable, and has a high ion binding rate and strong fluorescence signal; and the established TRFIA immunoassay has a high detection sensitivity.

A person skilled in the art should understand that each technical feature of the above examples may be in any combination; to achieve brief description, all the possible combinations of each technical feature of the above examples are not described one by one. But as long as the combinations of these technical features are not contradictory, the combinations should be regarded to fall within the scope of the description.

Claims (4)

CONCLUSIONS A labeling method for enhancing the signal intensity of time-resolved fluorescence, characterized by comprising the following steps: (1) weighing 4 to 7 mg of 2-5-{(4-aminophen1}-1,4,7-triazacyclononane -1,4,7-triacetic acid (p-NH2-Bn-NQOTA, herein referred to as NOTA), dissolving this in 1 mL of a 0.01 molL-1 4-{2-hydroxyethyl}-1-piperazineethane sulfonic acid (HEPES)- solution at pH 7.4 to obtain a NOTA chelating agent solution, the resulting solution being solution A; {2} adding 500 to 700 µL of a 20 mmol-L-1 glutaraldehyde solution to solution A, leaving overnight react at room temperature and protect from light, obtaining a solution B; (3) weighing 20 to 30 mg of a lyophilized powder of a purified monoclonal antibody, dissolving it in 3 mL of a HEPES solution (0.01 mol -L-1, pH 7.4} and mix well by magnetic stirring at room temperature, obtaining a solution C; (4) the add, dropwise, solution B to solution C, then adjust the pH to 9.0, stir to react for 4 to 6 hours at 4°C and protect from light, thereby obtaining a solution D; (5) place solution D in an 8-kDa MWCO (molecular weight cutoff) dialysis membrane and dialyze it with a HEPES solution (0.01 mol-L-1, pH 7.4}, changing fluids every 4 hours for a total of 4 to 6 exchanges, and then pipetting a reaction solution into the dialysis membrane to obtain a solution E; (6) weighing 0.11 to 0.15 g of EuCl3-6H20 and preparing a EuCl3- solution with 10 mL of ultrapure water, yielding a solution F; (7) adding 200 to 400 uL of solution F to solution E, reacting at room temperature for 4 to 6 hours protected from light, and then dialyzing in an 8 -kDa MWCO (molecular weight cutoff) dialysis membrane, with fluid changes every 4 hours for a total of 4 to 5 changes, then centrifuge for 3-5 times with a 30-kDa centrifugal ultrafiltration tube at 7000 to 9000 rpm, re-dissolve with 5 to 10 mL of 0.01 mol-L-1 HEPE S solution at pH 7.4, the prepared reaction solution being an olaquindox time-dissolved fluorescence immunolabeling antibody complex. A labeling method for enhancing the signal intensity of time-resolved fluorescence according to claim 1, characterized in that the monoclonal antibody is an olaguindox monoclonal antibody or a garamycin monoclonal antibody. 3. An application of 2-S-(4-aminophenyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid in improving the signal intensity of time-resolved fluorescence. An application of a labeling method for improving the signal intensity of time-resolved fluorescence in the detection of olaquindox or garamycin, characterized in that the labeling method is the method according to claim 1.